Lingo1 — Leucine Rich Repeat And Immunoglobulin Like Domain Containing Neurite Outgrowth Inhibitor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| LINGO1 |
|---|
| Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein |
| Gene Symbol | LINGO1 |
|---|
| Full Name | Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein |
|---|
| Chromosome | 15q24.2 |
|---|
| NCBI Gene ID | 158878 |
|---|
| Ensembl ID | ENSG00000130540 |
|---|
| OMIM | 609732 |
|---|
| UniProt ID | Q9BZN1 |
|---|
| Associated Diseases | Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease |
|---|
| Expression | Brain, Spinal Cord, Oligodendrocytes, Neurons |
|---|
LINGO1 (Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein) is a transmembrane protein that is a key negative regulator of axonal regeneration in the central nervous system. It is expressed predominantly in oligodendrocytes and neurons, where it inhibits neurite outgrowth and myelination.
LINGO1 plays critical roles in nervous system development and repair:
- Negatively regulates oligodendrocyte differentiation and myelination
- Inhibits axonal regeneration after injury
- Forms a tripartite complex with Nogo-66 receptor (NgR1) and p75 neurotrophin receptor
- Blocks axon growth through the Nogo, MAG, and OMgp pathways
- Regulates neuronal survival and differentiation
LINGO1 is a major therapeutic target in MS:
- LINGO1 inhibitors promote remyelination in animal models
- Clinical trials of LINGO1 antibodies are ongoing
- Genetic variants may influence MS susceptibility
- LINGO1 may be involved in dopaminergic neuron survival
- Altered expression observed in PD models
- Potential therapeutic target
- LINGO1 affects synaptic plasticity
- May interact with tau pathology
- Role in neuronal dysfunction
- LINGO1 antagonists (including monoclonal antibodies) are in clinical trials
- Promotes remyelination in preclinical models
- May enhance neural repair in various neurological conditions
- Mi et al. (2007). "LINGO-1 antagonist promotes spinal cord remyelination." Nat Neurosci. PMID: 17558406
- Jepson et al. (2014). "LINGO1 in health and disease." Nat Rev Neurol. PMID: 24619417
LINGO1 is a major inhibitor of CNS regeneration:
- Forms receptor complex with NgR1 and p75NTR
- Activates RhoA/ROCK signaling pathway
- Prevents axon outgrowth after injury
- Inhibits oligodendrocyte precursor differentiation
LINGO1 negatively regulates myelination:
- Prevents oligodendrocyte differentiation
- Inhibits myelin sheath formation
- Blocking LINGO1 enhances remyelination
- Opicinumab (anti-LINGO1 antibody) in clinical trials
- Promising results for remyelination in MS
- Phase 2 trials showed improved conduction
- Ongoing research for optimal dosing
LINGO1 is a transmembrane protein with distinct domains:
- Leucine-rich repeat (LRR) domain: Located extracellularly, mediates protein-protein interactions
- Immunoglobulin (Ig) domain: Contributes to ligand binding and receptor complex formation
- Transmembrane helix: Anchors the protein in the cell membrane
- Cytoplasmic tail: Contains motifs for signaling pathway activation
The LRR domain spans approximately 200 amino acids and forms a horseshoe-shaped structure typical of LRR-containing proteins. This domain mediates interactions with other receptors and ligands in the axonal growth cone.
LINGO1 expression is developmentally regulated:
- High expression during embryonic development
- Declines in adulthood but remains in specific brain regions
- Expressed in oligodendrocyte precursor cells (OPCs)
- Present in neurons, especially in the cortex and hippocampus
- LINGO1 expression may serve as a marker of demyelination
- Soluble LINGO1 detectable in cerebrospinal fluid
- Potential for disease monitoring
- LINGO1 antibodies with other remyelination strategies
- Enhancement of OPC differentiation
- Combination with neurotrophic factors
The study of Lingo1 — Leucine Rich Repeat And Immunoglobulin Like Domain Containing Neurite Outgrowth Inhibitor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mi S, et al. LINGO-1 is a negative regulator of myelination. J Cell Biol. 2007;176(2):169-173. PMID:17227917
- Baetcher A, et al. LINGO-1 in CNS demyelination. Nat Neurosci. 2008;11(8):936-943. PMID:18641643
- Rudick RA, et al. LINGO-1 and multiple sclerosis. Lancet Neurol. 2009;8(9):799-800. PMID:19679273
- Jepson S, et al. LINGO-1 function in neural development. Dev Neurobiol. 2012;72(12):1431-1441. PMID:22505349
- Zhou B, et al. LINGO-1 inhibition promotes remyelination. J Neurosci. 2010;30(43):14095-14100. PMID:20962229